Daiichi Sankyo Company, Limited (TYO: 4568)
Japan
· Delayed Price · Currency is JPY
4,551.00
-73.00 (-1.58%)
Nov 14, 2024, 3:45 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 446.55B JPY in the quarter ending September 30, 2024, with 18.92% growth. This brings the company's revenue in the last twelve months to 1.76T, up 25.84% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,758.07B
Revenue Growth
+25.84%
P/S Ratio
5.02
Revenue / Employee
93.88M
Employees
18,726
Market Cap
8,724.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDaiichi Sankyo Company News
- 2 days ago - Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS - Business Wire
- 7 days ago - ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product - Benzinga
- 14 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well - CNBC
- 15 days ago - Daiichi Sankyo Company, Limited 2024 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals - BNN Bloomberg
- 6 weeks ago - Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ... - GuruFocus
- 6 weeks ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy - Benzinga